Next Article in Journal
Previous Article in Journal
Previous Article in Special Issue
Cancers 2014, 6(2), 1098-1110; doi:10.3390/cancers6021098
Review

CCL21 Cancer Immunotherapy

1,2,3,4,5,* , 2,4,5,6
 and 1,2,3,4
Received: 1 March 2014; in revised form: 22 March 2014 / Accepted: 28 April 2014 / Published: 7 May 2014
(This article belongs to the Special Issue Cytokines in Cancer)
View Full-Text   |   Download PDF [503 KB, updated 8 May 2014; original version uploaded 7 May 2014]
Abstract: Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.
Keywords: CCL21; cancer immunotherapy; dendritic cell; polymer; T cell CCL21; cancer immunotherapy; dendritic cell; polymer; T cell
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Lin, Y.; Sharma, S.; John, M.S. CCL21 Cancer Immunotherapy. Cancers 2014, 6, 1098-1110.

AMA Style

Lin Y, Sharma S, John MS. CCL21 Cancer Immunotherapy. Cancers. 2014; 6(2):1098-1110.

Chicago/Turabian Style

Lin, Yuan; Sharma, Sherven; John, Maie S. 2014. "CCL21 Cancer Immunotherapy." Cancers 6, no. 2: 1098-1110.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert